Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6629-6637

  Tan, Min Han ^a,j   Morrison, Carl ^b   Wang, Pengfei ^a   Yang, Ximing ^c   Haven, Carola J ^d   Zhang, Chun ^a   Zhao, Ping ^a   Tretiakova, Maria S ^e   Korpi Hyovalti, Eeva ^f   Burgess, John M ^g   Khee, Chee Soo ^h   Cheah, Wei Keat ⁱ   Cao, Brian ^a   Resau, James ^a   Morreau, Hans ^d   Bin, Tean Teh ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CHICAGO   (United States)

^f SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF TASMANIA   (Australia)

^h SINGAPORE GENERAL HOSPITAL   (Singapore)

ⁱ NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^j ALEXANDRA HOSPITAL   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MONOCLONAL ANTIBODY; PARAFIBROMIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPARATHYROIDISM JAW TUMOR SYNDROME; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PARATHYROID CARCINOMA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; CELL LINE; DIAGNOSIS, DIFFERENTIAL; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; PARATHYROID NEOPLASMS; PROTEINS; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, PROTEIN; TUMOR SUPPRESSOR PROTEINS;

EID: 5144220874     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0493     Document Type: Article

References (50)

1. Grimelius L, Johansson H. Pathology of parathyroid tumors. Semin Surg Oncol 1997;13:142-54.
2. Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 2001;86:485-93.
3. Obara T, Okamoto T, Kanbe M, Iihara M. Functioning parathyroid carcinoma: clinicopathologic features and rational treatment. Semin Surg Oncol 1997;13:134-41.
4. Favia G, Lumachi F, Polistina F, D'Amico DF. Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg 1998;22:1225-30.
5. Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol 2004;202:86-94.
6. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer (Phila) 1999;86:538-44.
7. Dotzenrath C, Goretzki PE, Sarbia M, Cupisti K, Feldkamp J, Roher HD. Parathyroid carcinoma: problems in diagnosis and the need for radical surgery even in recurrent disease. Eur J Surg Oncol 2001;27:383-9.
8. Sandelin K, Tullgren O, Farnebo LO. Clinical course of metastatic parathyroid cancer. World J Surg 1994;18:594-8; discussion 599.
9. Hara H, Oyama T, Kimura M, et al. Cytologic characteristics of parathyroid carcinoma: a case report. Diagn Cytopathol 1998;18:192-8.
10. Wells SA Jr, Debenedetti MK, Doherty GM. Recurrent or persistent hyperparathyroidism. J Bone Miner Res 2002;17(Suppl 2):N158-62.
11. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003;349:1722-9.
12. Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 1990;108:1006-12; discussion 1012-3.
13. Weinstein LS, Simonds WF, HRPT2, a marker of parathyroid cancer. N Engl J Med 2003;349:1691-2.
14. Clayman GL, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer (Phila) 2004;100:900-5.
15. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002;32:676-80.
16. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003;40:657-63.
17. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer (Phila) 1973;31:600-5.
18. Naccarato AG, Marcocci C, Miccoli P, et al. Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues. J Endocrinol Investig 1998;21:136-41.
19. Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 2003;34:54-64.
20. Erickson LA, Jin L, Papotti M, Lloyd RV. Oxyphil parathyroid carcinomas: a clinicopathologic and immunohistochemical study of 10 cases. Am J Surg Pathol 2002;26:344-9.
21. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol 1999;23:288-95.
22. Farnebo F, Auer G, Farnebo LO, et al. Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg 1999;23:68-74.
23. Lloyd RV, Carney JA, Ferreiro JA, et al. Immunohistochemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas. Endocr Pathol 1995; 6:279-287.
24. Vargas MP, Vargas HI, Kleiner DE, Merino MJ. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 1997;10:12-7.
25. Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994; 330:757-61.
26. Cetani F, Pardi E, Viacava P, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 2004;60:99-106.
27. Levin KE, Chew KL, Ljung BM, Mayall BH, Siperstein AE, Clark OH. Deoxyribonucleic acid cytometry helps identify parathyroid carcinomas. J Clin Endocrinol Metab 1988;67:779-84.
28. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 1993;17:820-9.
29. August DA, Flynn SD, Jones MA, Bagwell CB, Kinder BK. Parathyroid carcinoma: the relationship of nuclear DNA content to clinical outcome. Surgery 1993;113:290-6.
30. Obara T, Fujimoto Y, Kanaji Y, et al. Flow cytometric DNA analysis of parathyroid tumors. Implication of aneuploidy for pathologic and biologic classification. Cancer (Phila) 1990;66:1555-62.
31. Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo LO. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 1992; 16:724-31.
32. Haven CJ, Howell VM, Eilers PHC, Dunne R, Takahashi M, van Puijenbroek M, Furge KA, Tan MH, Kievit J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Dralle H, Hoang-Vu C, Gimm O, Morreau H, Marsh DJ, Teh BT. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Research (in press).
33. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
34. Haven CJ, Wong FK, van Dam EW, et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2000;85:1449-54.
35. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-72.
36. Gattiker A, Gasteiger E, Bairoch A. ScanProsite: a reference implementation of a PROSITE scanning tool. Appl Bioinformatics 2002; 1:107-8.
37. Sawady J, Mendelsohn G, Sirota RL, Taxy JB. The intrathyroidal hyperfunctioning parathyroid gland. Mod Pathol 1989;2:652-7.
38. Shi X, Chang M, Wolf AJ, et al. Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme. Mol Cell Biol 1997;17:1160-9.
39. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994;271:703-7.
40. Levin KE, Galante M, Clark OH. Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 1987;101:649-60.
41. Goshen O, Aviel-Ronen S, Dori S, Talmi YP. Brown tumour of hyperparathyroidism in the mandible associated with atypical parathyroid adenoma. J Laryngol Otol 2000;114:302-4.
42. Marx SJ, Simonds WF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 2002;17(Suppl 2):N37-43.
43. Dotzenrath C, Teh BT, Farnebo F, et al. Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 1996;81:3194-6.
44. Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 1996;45:195-200.
45. Kytola S, Farnebo F, Obara T, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 2000;157:579-86.
46. Yoshimoto K, Endo H, Tsuyuguchi M, et al. Familial isolated primary hyperparathyroidism with parathyroid carcinomas: clinical and molecular features. Clin Endocrinol (Oxf) 1998;48:67-72.
47. Shattuck TM, Kim TS, Costa J, et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf) 2003;59:180-9.
48. Dionisi S, Minisola S, Pepe J, et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc 2002;77:866-9.
49. Sato M, Miyauchi A, Namihira H, et al. A newly recognized germline mutation of MEN1 gene identified in a patient with parathyroid adenoma and carcinoma. Endocrine 2000;12:223-6.
50. Richter T, Nahrig J, Komminoth P, Kowolik J, Werner M. Protocol for ultrarapid immunostaining of frozen sections. J Clin Pathol 1999; 52:461-3.